U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19N5
Molecular Weight 245.324
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PINACIDIL ANHYDROUS

SMILES

CC(C(C)(C)C)NC(=NC#N)N=c1cc[nH]cc1

InChI

InChIKey=IVVNZDGDKPTYHK-UHFFFAOYSA-N
InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)

HIDE SMILES / InChI
Pinacidil is a clinically effective vasodilator used for the treatment of hypertension.

CNS Activity

Curator's Comment:: Pinacidil does not have a high propensity for crossing the blood/brain barrier

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
69.7 ng/mL
12.5 mg 2 times / day multiple, oral
dose: 12.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PINACIDIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
365.4 ng × h/mL
12.5 mg 2 times / day multiple, oral
dose: 12.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PINACIDIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.7 h
12.5 mg 2 times / day multiple, oral
dose: 12.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PINACIDIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Other AEs: Headache, Edema...
Other AEs:
Headache (9.7%)
Edema (29%)
Dizziness (9.7%)
Asthenia (3.2%)
Tachycardia (12.9%)
Palpitation (3.2%)
Sources:
25 mg 2 times / day multiple, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, 53.6 ± 11.0 years
Health Status: unhealthy
Age Group: 53.6 ± 11.0 years
Sex: M+F
Sources:
Disc. AE: Edema, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Edema (5.9%)
Tachycardia (3.4%)
Sources:
37.5 mg 2 times / day multiple, oral
Dose: 37.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 37.5 mg, 2 times / day
Sources:
unhealthy, 53.6 ± 11.0 years
Health Status: unhealthy
Age Group: 53.6 ± 11.0 years
Sex: M+F
Sources:
Disc. AE: Edema...
AEs leading to
discontinuation/dose reduction:
Edema (18.8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Tachycardia 12.9%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Edema 29%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Asthenia 3.2%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Palpitation 3.2%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Dizziness 9.7%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Headache 9.7%
75 mg 2 times / day multiple, oral
Highest studied dose
Dose: 75 mg, 2 times / day
Route: oral
Route: multiple
Dose: 75 mg, 2 times / day
Sources:
unhealthy, 53.1 years
n = 31
Health Status: unhealthy
Age Group: 53.1 years
Sex: M+F
Population Size: 31
Sources:
Tachycardia 3.4%
Disc. AE
25 mg 2 times / day multiple, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, 53.6 ± 11.0 years
Health Status: unhealthy
Age Group: 53.6 ± 11.0 years
Sex: M+F
Sources:
Edema 5.9%
Disc. AE
25 mg 2 times / day multiple, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, 53.6 ± 11.0 years
Health Status: unhealthy
Age Group: 53.6 ± 11.0 years
Sex: M+F
Sources:
Edema 18.8%
Disc. AE
37.5 mg 2 times / day multiple, oral
Dose: 37.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 37.5 mg, 2 times / day
Sources:
unhealthy, 53.6 ± 11.0 years
Health Status: unhealthy
Age Group: 53.6 ± 11.0 years
Sex: M+F
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.
1996 Oct 4
Patents

Patents

Sample Use Guides

Adults: Oral: 12.5 mg twice daily, may increase at intervals of 1-2 weeks; maximum dose: 100-150 mg/day in divided doses
Route of Administration: Oral
In murine WT ventricular cells, pinacidil (1-100uM) concentration-dependently induced an outward current and action potential shortening, effects that were blocked by glibenclamide, a K(ATP) channel blocker.
Name Type Language
PINACIDIL ANHYDROUS
Common Name English
(+/-)-PINACIDIL
Common Name English
PINACIDIL [WHO-DD]
Common Name English
GUANIDINE, N-CYANO-N'-4-PYRIDINYL-N''-(1,2,2-TRIMETHYLPROPYL)-
Systematic Name English
(R,S)-PINACIDIL
Common Name English
PINACIDIL [MI]
Common Name English
P-1134
Code English
1-(3,3-DIMETHYLBUTAN-2-YL)-2-CYANO-3-(PYRIDIN-4-YL)GUANIDINE
Systematic Name English
PINACIDIL [INN]
Common Name English
S-1230
Code English
GUANIDINE, N''-CYANO-N-4-PYRIDINYL-N'-(1,2,2-TRIMETHYLPROPYL)-,(+/-)-
Common Name English
Classification Tree Code System Code
WHO-ATC C02DG01
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
NCI_THESAURUS C270
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
Code System Code Type Description
MERCK INDEX
M8819
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY Merck Index
PUBCHEM
4826
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
FDA UNII
BB4UGO5K0D
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
INN
5013
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
CAS
113563-69-2
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
SUPERSEDED
EPA CompTox
60560-33-0
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
CAS
60560-33-0
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
ECHA (EC/EINECS)
262-294-9
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
NCI_THESAURUS
C143025
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY
EVMPD
SUB09848MIG
Created by admin on Sat Jun 26 10:48:34 UTC 2021 , Edited by admin on Sat Jun 26 10:48:34 UTC 2021
PRIMARY